🇺🇸 FDA
Pipeline program

DEXLANSOPRAZOLE PEDIATRIC, DEXLANSOPRAZOLE PEDIATRIC, DEXLANSOPRAZOLE PEDIATRIC

TAK-390MR_205

Phase 2 small_molecule active

Quick answer

DEXLANSOPRAZOLE PEDIATRIC, DEXLANSOPRAZOLE PEDIATRIC, DEXLANSOPRAZOLE PEDIATRIC for Erosive Esophagitis is a Phase 2 program (small_molecule) at Takeda with 1 ClinicalTrials.gov record(s).

Program details

Company
Takeda
Indication
Erosive Esophagitis
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials